Exelixis Says Glaxo Deal Raises Profile for Role of Genomics in Drug Discovery | GenomeWeb

SAN FRANCISCO, Oct. 29 - The GlaxoSmithKline alliance with Exelixis announced Monday validates the use of genomics in drug discovery and could lead to similar deals, said Exelixis Chief Scientific Officer Geoffrey Duyk.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.